Product Code: GVR-1-68038-023-1
The global molecular cytogenetics market size is expected to reach USD 3. 8 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a 10.4% CAGR during the forecast period. Mapping of human genome, coupled with continuous technological advancements in cytogenetic techniques, has enabled researchers to gain insight into the disease-causing mechanism at a genomic as well as cellular level. Development in molecular technologies has helped in bridging the gap between molecular biology and cytogenetics, which was not possible using conventional cytogenetic techniques.
There is a continuous growth in awareness, and consequent adoption, of genetic tests for disease prognosis. These tests also help in designing further treatment regimes for widespread chromosomal abnormalities. This is sure to boost market growth.
Incorporation of high throughput sequencers in cytogenetic analysis is expected to significantly enhance market growth in the coming years. A number of researchers and scientists have begun converging cytogenetics laboratories with NGS as they complement each other. Hence, with exponential decline in sequencing price, this market is expected to grow at a lucrative pace.
However, ambiguous regulatory and reimbursement scenario in certain regions pertaining to implementation of genetic tests is expected to hamper the adoption of molecular cytogenetic techniques to a certain extent.
Further key findings from the report suggest:
- Oncology held the largest share in the market in 2016 owing to the ability of CGH technology to facilitate in-depth studies for cancer etiology
- Use of molecular cytogenetics in personalized medicine development is expected to grow lucratively during the forecast period. This is majorly due to a continuous shift toward targeted therapies for effective disease management
- Requirement of consumables in the entire cytogenetics process is attributive for the largest share of this product category
- Ongoing research projects for developing treatment regimen of different genetic conditions have allowed clinical and research laboratories to gain a significant share in the market
- Pharmaceutical and biotech companies are expected to be a key source of revenue in the coming years. This is mainly because a number of pharmaceutical companies have expanded their business in the field of personalized medicine
- Illumina, Inc.; Agilent Technologies, Inc.; Abbott; Bio-Rad Laboratories, Inc.; and Oxford Gene Technology are some prominent companies in the market. They are involved in development and commercialization of cytogenetics techniques
- Some major service providers are Weill Cornell Medicine; WiCell Research Institute, Inc.; ARUP Laboratories; and Integrated Systems Engineering S.r.l.
Table of Content
Chapter 1: Executive Summary
Chapter 2: Research Methodology
- 2.1. Information Procurement
- 2.2. Information or Data Analysis
- 2.3. Market Formulation & Validation
Chapter 3: Molecular Cytogenetics Market Variables, Trends & Scope
- 3.1. Market Segmentation & Scope
- 3.1.1. Market driver analysis
- 3.1.1.1. Growing implementation of pharmacogenomics in personalized disease management and drug development
- 3.1.1.2. Rising cancer cases
- 3.1.1.3. Gradual advancements in cytogenetic techniques
- 3.1.1.3.1. Transition from array based technology to NGS technology
- 3.1.1.4. Growth in gene-based prediction of genetic abnormalities
- 3.1.1.5. Increasing importance molecular cytogenetic in crop improvement
- 3.1.1.6. Aging population & its vulnerability to chronic diseases
- 3.1.2. Market restraint analysis
- 3.1.2.1. High cost of instruments has restricted the adoption of cytogenetic techniques in developing and emerging nations
- 3.1.2.2. Lack of skilled personnel
- 3.1.2.3. Ambiguous regulatory & reimbursement scenario
- 3.2. Molecular Cytogenetics -Swot Analysis, By Factor(Political & Legal, Economic And Technological)
- 3.3. Industry Analysis-Porter's
- 3.4. Automation in Cytogenetic Laboratory: Demand and Implementation
- 3.4.1. Demand
- 3.4.1.1. Demand for development of automated sequencing technology:
- 3.4.2. Implementation
- 3.5. Costs of cytogenetics services offered by prominent players operating in this space
- 3.6. Cost comparison based on technique used in cytogenetic analysis
- 3.7. Service demand and the nature of services provided
- 3.8. Major service based contracts in the market
- 3.9. Opportunities with respect to service offerings in cytogenetics
- 3.10. Services for diagnostics
- 3.11. Services for research
Chapter 4: Molecular Cytogenetics: Application Estimates & Trend Analysis
- 4.1. Molecular Cytogenetics Market: Application Movement Analysis
- 4.2. Penetration & Growth Prospect Mapping for Application, 2016
- 4.3. Genetic Disorders
- 4.3.1. Global genetic disorders market, 2014-2025(USD Million)
- 4.4. Oncology
- 4.4.1. Global oncology market, 2014-2025(USD Million)
- 4.5. Personalized Medicine
- 4.5.1. Global personalized medicine market, 2014-2025(USD Million)
- 4.6. Other Applications
- 4.6.1. Global other applications market, 2014-2025(USD Million)
Chapter 5: Molecular Cytogenetics: Product Estimates & Trend Analysis
- 5.1. Global Molecular Cytogenetics Market: Product Movement Analysis
- 5.2. Penetration & Growth Prospect Mapping for Product, 2016
- 5.3. Instruments
- 5.3.1. Global instruments market, 2014-2025(USD Million)
- 5.4. Consumables
- 5.4.1. Global consumables market, 2014-2025(USD Million)
- 5.5. Software & Services
- 5.5.1. Global software & services market, 2014-2025(USD Million)
Chapter 6: Molecular Cytogenetics: End-use Estimates & Trend Analysis
- 6.1. Molecular Cytogenetics Market: End-use Movement Analysis
- 6.2. Penetration & Growth Prospect Mapping for End-use, 2016
- 6.3. Clinical & Research Laboratories
- 6.4. Clinical Cytogenetics
- 6.4.1. New cancer cases, U.S.
- 6.4.2. Global clinical & research laboratories market, 2014-2025(USD Million)
- 6.5. Hospitals & Pathology Laboratories
- 6.5.1. Global hospitals & pathology laboratories market, 2014-2025(USD Million)
- 6.6. Academic Research Institutes
- 6.6.1. Global academic research institutes market, 2014-2025(USD Million)
- 6.7. Pharmaceutical and Biotechnology Companies
- 6.7.1. Global pharmaceutical and biotechnology companies market, 2014-2025(USD Million)
- 6.8. Other End Users
- 6.8.1. Global other end users market, 2014-2025(USD Million)
Chapter 7: Molecular Cytogenetics: Technology Estimates & Trend Analysis
- 7.1. Global Molecular Cytogenetics Market: Technology Movement Analysis
- 7.1.1. Comparative analysis of technologies
- 7.1.1.1. Comparative analysis of various molecular cytogenetic techniques
- 7.1.1.2. Comparative analysis of conventional and molecular cytogenetic techniques
- 7.2. Penetration & Growth Prospect Mapping for Technology, 2016
- 7.3. Comparative Genomic Hybridization
- 7.3.1. Global comparative genomic hybridization market, 2014-2025(USD Million)
- 7.3.2. Array-based comparative genomic hybridization
- 7.3.2.1. Global array-based comparative genomic hybridization market, 2014-2025(USD Million)
- 7.3.3. Standard comparative genomic hybridization
- 7.3.3.1. Global standard comparative genomic hybridization market, 2014-2025(USD Million)
- 7.4. Fluorescence In Situ Hybridization(FISH)
- 7.4.1. Global fluorescence in situ hybridization market, 2014-2025(USD Million)
- 7.5. Immunohistochemistry
- 7.5.1. Global immunohistochemistry market, 2014-2025(USD Million)
- 7.6. Karyotyping
- 7.6.1. Global karyotyping market, 2014-2025(USD Million)
- 7.6.2. Spectral karyotyping
- 7.6.2.1. Global spectral karyotyping market, 2014-2025(USD Million)
- 7.6.3. Virtual karyotyping
- 7.6.3.1. Global virtual karyotyping market, 2014-2025(USD Million)
- 7.7. Other Techniques
- 7.7.1. Global other techniques market, 2014-2025(USD Million)
Chapter 8: Molecular Cytogenetics: Regional Estimates & Trend Analysis, by Application, Product, End-use, & Technology
- 8.1. Molecular Cytogenetics Market Share By Region, 2015 & 2025
- 8.2. North America
- 8.2.1. North America molecular cytogenetics market, 2014-2025(USD Million)
- 8.2.2. U.S.
- 8.2.2.1. U.S. molecular cytogenetics culture market, by application, 2014-2025(USD Million)
- 8.2.2.2. U.S. molecular cytogenetics culture market, by product, 2014-2025(USD Million)
- 8.2.2.3. U.S. molecular cytogenetics culture market, by end-use, 2014-2025(USD Million)
- 8.2.2.4. U.S. molecular cytogenetics culture market, by technology, 2014-2025(USD Million)
- 8.2.3. Canada
- 8.2.3.1. Canada molecular cytogenetics market, by application, 2014-2025(USD Million)
- 8.2.3.2. Canada molecular cytogenetics market, by product, 2014-2025(USD Million)
- 8.2.3.3. Canada molecular cytogenetics market, by end-use, 2014-2025(USD Million)
- 8.2.3.4. Canada molecular cytogenetics market, by technology,2014-2025(USD Million)
- 8.3. Europe
- 8.3.1. Europe molecular cytogenetics market, 2014-2025(USD Million)
- 8.3.2. Germany
- 8.3.2.1. Germany molecular cytogenetics market, by application, 2014-2025(USD Million)
- 8.3.2.2. Germany molecular cytogenetics market, by product, 2014-2025(USD Million)
- 8.3.2.3. Germany molecular cytogenetics market, by end-use, 2014-2025(USD Million)
- 8.3.2.4. Germany molecular cytogenetics market, by technology,2014-2025(USD Million)
- 8.3.3. U.K.
- 8.3.3.1. U.K. molecular cytogenetics market, by application, 2014-2025(USD Million)
- 8.3.3.2. U.K. molecular cytogenetics market, by product, 2014-2025(USD Million)
- 8.3.3.3. U.K. molecular cytogenetics market, by end-use, 2014-2025(USD Million)
- 8.3.3.4. U.K. molecular cytogenetics market, by technology,2014-2025(USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific molecular cytogenetics market, 2014-2025(USD Million)
- 8.4.2. Japan
- 8.4.2.1. Japan molecular cytogenetics market, by application, 2014-2025(USD Million)
- 8.4.2.2. Japan molecular cytogenetics market, by product, 2014-2025(USD Million)
- 8.4.2.3. Japan molecular cytogenetics market, by end-use, 2014-2025(USD Million)
- 8.4.2.4. Japan molecular cytogenetics market, by technology,2014-2025(USD Million)
- 8.4.3. China
- 8.4.3.1. China molecular cytogenetics market, by application, 2014-2025(USD Million)
- 8.4.3.2. China molecular cytogenetics market, by product, 2014-2025(USD Million)
- 8.4.3.3. China molecular cytogenetics market, by end-use, 2014-2025(USD Million)
- 8.4.3.4. China molecular cytogenetics market, by technology,2014-2025(USD Million)
- 8.5. Latin America
- 8.5.1. Latin America molecular cytogenetics market, 2014-2025(USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Brazil molecular cytogenetics market, by application, 2014-2025(USD Million)
- 8.5.2.2. Brazil molecular cytogenetics market, by product, 2014-2025(USD Million)
- 8.5.2.3. Brazil molecular cytogenetics market, by end-use, 2014-2025(USD Million)
- 8.5.2.4. Brazil molecular cytogenetics market, by technology,2014-2025(USD Million)
- 8.6. Middle East & Africa
- 8.6.1. Middle East & Africa molecular cytogenetics market, 2014-2025(USD Million)
- 8.6.2. South Africa
- 8.6.2.1. South Africa molecular cytogenetics market, by application, 2014-2025(USD Million)
- 8.6.2.2. South Africa molecular cytogenetics market, by product, 2014-2025(USD Million)
- 8.6.2.3. South Africa molecular cytogenetics market, by end-use, 2014-2025(USD Million)
- 8.6.2.4. South Africa molecular cytogenetics market, by technology,2014-2025(USD Million)
Chapter 9: Competitive Landscape
- 9.1. Strategy Framework
- 9.2. Market Participation Categorization
- 9.3. Company market share analysis
- 9.3.1. Company size
- 9.3.2. Product portfolio
- 9.3.3. Geographical presence
- 9.3.4. Mergers and collaborations
- 9.3.5. Distribution networks
- 9.3.6. Segment coverage
- 9.3.7. Conclusion
- 9.4. Company Profiles
- 9.4.1. BIOVIEW
- 9.4.1.1. Company overview
- 9.4.1.2. Financial performance
- 9.4.1.3. Product benchmarking
- 9.4.1.4. Strategic initiatives
- 9.4.2. Danaher
- 9.4.2.1. Company overview
- 9.4.2.1.1. Leica Biosystems Nussloch GmbH
- 9.4.2.2. Financial performance
- 9.4.2.2.1. Financial performance
- 9.4.2.3. Product benchmarking
- 9.4.2.4. Strategic initiatives
- 9.4.3. MetaSystems
- 9.4.3.1. Company overview
- 9.4.3.2. Financial performance
- 9.4.3.3. Product benchmarking
- 9.4.3.4. Strategic initiatives
- 9.4.4. Agilent Technologies, Inc.
- 9.4.4.1. Company overview
- 9.4.4.2. Financial performance
- 9.4.4.3. Product benchmarking
- 9.4.4.4. Strategic initiatives
- 9.4.5. Abbott
- 9.4.5.1. Company overview
- 9.4.5.2. Financial performance
- 9.4.5.3. Product benchmarking
- 9.4.5.4. Strategic initiatives
- 9.4.6. Bio-Rad Laboratories, Inc.
- 9.4.6.1. Company overview
- 9.4.6.2. Financial performance
- 9.4.6.3. Product benchmarking
- 9.4.6.4. Strategic initiatives
- 9.4.7. Illumina, Inc.
- 9.4.7.1. Company overview
- 9.4.7.2. Financial performance
- 9.4.7.3. Product benchmarking
- 9.4.7.4. Strategic initiatives
- 9.4.8. Oxford Gene Technology
- 9.4.8.1. Company overview
- 9.4.8.2. Financial performance
- 9.4.8.3. Product benchmarking
- 9.4.8.4. Strategic initiatives
- 9.4.9. F. Hoffmann-La Roche Ltd
- 9.4.9.1. Company overview
- 9.4.9.1.1. Genentech, Inc.
- 9.4.9.2. Financial performance
- 9.4.9.3. Financial performance
- 9.4.9.4. Product benchmarking
- 9.4.9.5. Strategic initiatives
- 9.4.10. PerkinElmer Inc.
- 9.4.10.1. Company overview
- 9.4.10.2. Financial performance
- 9.4.10.3. Product benchmarking
- 9.4.10.4. Strategic initiatives
- 9.4.11. Quest Diagnostics Incorporated
- 9.4.11.1. Company overview
- 9.4.11.1.1. Sonora Quest Laboratories
- 9.4.11.2. Financial performance
- 9.4.11.2.1. Financial performance
- 9.4.11.3. Product benchmarking
- 9.4.11.4. Product benchmarking
- 9.4.11.5. Strategic initiatives
- 9.4.12. Applied Spectral Imaging
- 9.4.12.1. Company overview
- 9.4.12.2. Financial performance
- 9.4.12.3. Product benchmarking
- 9.4.12.4. Strategic initiatives
- 9.4.13. Biological Industries USA, Inc.
- 9.4.13.1. Company overview
- 9.4.13.2. Financial performance
- 9.4.13.3. Product benchmarking
- 9.4.13.4. Strategic initiatives
- 9.4.14. CytoTest
- 9.4.14.1. Company overview
- 9.4.14.2. Financial performance
- 9.4.14.3. Product benchmarking
- 9.4.14.4. Strategic initiatives
- 9.4.15. Cytognomix
- 9.4.15.1. Company overview
- 9.4.15.2. Financial performance
- 9.4.15.3. Product benchmarking
- 9.4.16. Genial Genetics
- 9.4.16.1. Company overview
- 9.4.16.2. Financial performance
- 9.4.16.3. Product benchmarking
- 9.4.16.4. Strategic initiatives
- 9.4.17. Diagnostic Cytogenetics, Inc.(DCI)
- 9.4.17.1. Company overview
- 9.4.17.2. Financial performance
- 9.4.17.3. Product benchmarking
- 9.4.18. Hospital/standalone laboratory/University/Academic institute based cytogenetic services
- 9.4.18.1. Weill Cornell Medicine
- 9.4.18.1.1. Company overview
- 9.4.18.1.2. Financial performance
- 9.4.18.1.3. Service benchmarking
- 9.4.18.2. UCLA Health-UCLA Pathology and Laboratory Medicines
- 9.4.18.2.1. Company overview
- 9.4.18.2.2. Financial performance
- 9.4.18.2.3. Service benchmarking
- 9.4.18.3. OHSU School of Medicine-Molecular and Medical Genetics
- 9.4.18.3.1. Company overview
- 9.4.18.3.2. Financial performance
- 9.4.18.3.3. Service benchmarking
- 9.4.18.4. Integrated Systems Engineering S.r.l.
- 9.4.18.4.1. Company overview
- 9.4.18.4.2. Financial performance
- 9.4.18.4.3. Product benchmarking
- 9.4.18.5. WiCell Research Institute, Inc.
- 9.4.18.5.1. Company overview
- 9.4.18.5.2. Financial performance
- 9.4.18.5.3. Product benchmarking
- 9.4.18.6. Virtual Scientific
- 9.4.18.6.1. Company overview
- 9.4.18.6.2. Financial performance
- 9.4.18.6.3. Product benchmarking
- 9.4.18.7. UW Cytogenetic Services
- 9.4.18.7.1. Company overview
- 9.4.18.7.2. Financial performance
- 9.4.18.7.3. Service benchmarking
- 9.4.18.8. Genesis Laboratories Inc.
- 9.4.18.8.1. Company overview
- 9.4.18.8.2. Financial performance
- 9.4.18.8.3. Product benchmarking
- 9.4.18.9. Calgary Laboratory Services
- 9.4.18.9.1. Company overview
- 9.4.18.9.2. Financial performance
- 9.4.18.9.3. Product benchmarking
- 9.4.18.10. Neogenomics
- 9.4.18.10.1. Company overview
- 9.4.18.10.2. Financial performance
- 9.4.18.10.3. Product benchmarking
- 9.4.18.11. ARUP Laboratories
- 9.4.18.11.1. Company overview
- 9.4.18.11.2. Financial performance
- 9.4.18.11.3. Product benchmarking
- 9.4.18.11.4. Strategic initiatives
- 9.4.18.12. South West Thames Regional Genetics Service
- 9.4.18.12.1. Company overview
- 9.4.18.12.2. Financial performance
- 9.4.18.12.3. Service benchmarking
